Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Oxidase

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    98 result(s) found for: Oxidase. Displaying page 1 of 5.
    1  2  3  4  5  Next»
    EudraCT Number: 2013-002701-56 Sponsor Protocol Number: ALXN1101-MCD-201 Start Date*: 2014-04-16
    Sponsor Name:Origin Biosciences, Inc.
    Full Title: A Phase 2, multicenter, multinational, open-label, dose-escalation study to evaluate the safety and efficacy of ORGN001 (formerly ALXN1101) in pediatric patients with Molybdenum Cofactor Deficiency...
    Medical condition: Molybdenum Cofactor Deficiency (MoCD) Type A
    Disease: Version SOC Term Classification Code Term Level
    20.1 10010331 - Congenital, familial and genetic disorders 10069687 Molybdenum cofactor deficiency PT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) NL (Completed)
    Trial results: View results
    EudraCT Number: 2013-002702-30 Sponsor Protocol Number: ALXN1101-MCD-202 Start Date*: Information not available in EudraCT
    Sponsor Name:Origin Biosciences, Inc.
    Full Title: A PHASE 2/3, MULTICENTER, MULTINATIONAL, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ALXN1101 IN NEONATES WITH MOLYBDENUM COFACTOR DEFICIENCY (MOCD) TYPE A
    Medical condition: Molydenum CoFactor Deficiency (MoCD) Type A
    Disease: Version SOC Term Classification Code Term Level
    20.1 10010331 - Congenital, familial and genetic disorders 10069687 Molybdenum cofactor deficiency PT
    Population Age: Newborns, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) ES (Completed) FR (Completed) IT (Prematurely Ended) NO (Completed)
    Trial results: View results
    EudraCT Number: 2005-006113-40 Sponsor Protocol Number: KARD-12-2005 Start Date*: 2006-05-03
    Sponsor Name:Universitäres Herzzentrum Hamburg
    Full Title: Untersuchung der Modulation der Endothelfunktion durch Enoxaparin bei Patienten mit Koronarkrankheit. Bedeutung der Enoxaparin-vermittelten Dissoziation endothelial gebundener Oxidasen für die Regu...
    Medical condition: Stabile koronare Herzerkrankung
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-003541-17 Sponsor Protocol Number: ALMU_2011 Start Date*: 2011-11-22
    Sponsor Name:Instituo de Investigacion Sanitaria La Fe
    Full Title: EFFECT OF THE ADMINISTRATION OF ALLOPURINOL ON THE PREVENTION OF MUSCLE MASS LOSS IN IMMOBILIZED SUBJECTS.
    Medical condition: Immobilized subjects.
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2006-000001-27 Sponsor Protocol Number: KARD-07-2006 Start Date*: 2007-04-12
    Sponsor Name:Universitäres Herzzentrum, Klinik für Kardiologie und Angiologie
    Full Title: Untersuchung der antiinflammatorischen Eigenschaften von Clopidogrel im Vergleich zu Acetylsalicylsäure bei Patienten mit chronischer ischämischer Kardiomyopathie
    Medical condition: Das Ziel dieser Untersuchung ist es, zu evaluieren, ob und welche antiinflammatorischen Effekte Clopidogrel 75 mg im Vergleich zu Acetylalicylsäure (ASS) 100 mg bei Patienten mit chronischer ischäm...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-003081-42 Sponsor Protocol Number: Jus002 Start Date*: 2005-10-06
    Sponsor Name:University of DUndee
    Full Title: EXPLORING THE THERAPEUTIC POTENTIAL OF XANTHINE OXIDASE INHIBITORS IN CORONARY ARTERY DISEASE
    Medical condition: Ishaemic heart disease; Angina, acute myocardial infarction
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-001725-26 Sponsor Protocol Number: X-CGD-Version2 Start Date*: 2013-03-12
    Sponsor Name:Johann Wolfgang Goethe-University
    Full Title: A Phase I/II Gene Therapy trial for X-CGD with a SIN gamma retroviral vector
    Medical condition: Chronic granulomatous disease (CGD) is a congenital immunodeficiency, in which neutrophil granulocytes and monocytes are not capable of producing reactive oxygen species and therefore are unable to...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10010331 - Congenital, familial and genetic disorders 10008906 Chronic granulomatous disease PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2004-005103-16 Sponsor Protocol Number: ETF 5450 Start Date*: 2005-02-09
    Sponsor Name:Estonian Science Foundation
    Full Title: Central serotonergic activity measured by citalopram challenge test and platelet monoamine oxidase activity, associations with gene polymorphism (5-HTTLPR) and impulsivity
    Medical condition: Healthy volunteers
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: EE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-001191-30 Sponsor Protocol Number: RDEA594-401 Start Date*: 2017-09-27
    Sponsor Name:Ironwood Pharmaceuticals, Inc.
    Full Title: A Phase 4, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lesinurad 200 mg in Combination With a Xanthine Oxidase Inhibitor (XOI), Compared W...
    Medical condition: Gout and moderate renal impairment
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10018627 Gout PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended) HU (Prematurely Ended) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-000242-35 Sponsor Protocol Number: G1XCGD.01 Start Date*: 2013-01-10
    Sponsor Name:Genethon
    Full Title: A phase I/II, non randomized, multicenter, open-label study of autologous CD34+ cells transduced with the G1XCGD Lentiviral vector in patients with X-Linked Chronic Granulomatous Disease
    Medical condition: X-linked Chronic Granulomatous Disease
    Disease: Version SOC Term Classification Code Term Level
    19.0 10010331 - Congenital, familial and genetic disorders 10008906 Chronic granulomatous disease PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-000891-54 Sponsor Protocol Number: REBOOT-II Start Date*: 2016-11-28
    Sponsor Name:Aging Research Center, Karolinska Institutet and Stockholm University
    Full Title: Effects of enhanced dopaminergic neurotransmission on working memory training efficiency in the healthy elderly - A prospective, single center, randomized, double blind, placebo controlled, paralle...
    Medical condition: No medical condition is under investigation. The project investigates normal age-related decline in intellectual abilities.
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-000335-17 Sponsor Protocol Number: MPR001 Start Date*: 2014-10-28
    Sponsor Name:Research and Development University Hospital of North Staffordshire [...]
    1. Research and Development University Hospital of North Staffordshire
    2. Keele University
    Full Title: The Effect of Rotigotine on Memory in Idiopathic Parkinson's Disease without Cognitive Impairment
    Medical condition: Idiopathic Parkinson's Disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-000294-78 Sponsor Protocol Number: CTP001H Start Date*: 2019-06-07
    Sponsor Name:Nektr Technologies
    Full Title: A Randomized, Single-Blinded, Comparative Study of Mycosinate and Curanail in the Treatment of Fungal Nail Infection
    Medical condition: Onychomycosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: IE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-002222-12 Sponsor Protocol Number: G1XCGD.02 Start Date*: 2015-10-08
    Sponsor Name:Genethon
    Full Title: A phase I/II, non-randomized, monocentric, open-label study of autologous CD34+ cells transduced with the G1XCGD lentiviral vector in patients with X-Linked Chronic Granulomatous Disease.
    Medical condition: Chronic Granulomatous Disease (CGD) is a rare inherited disorder (1/250,000) of the phagocytes characterized by the inability of phagocytes (monocytes and neutrophils) to produce reactive oxygen sp...
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2005-001669-33 Sponsor Protocol Number: tsa1 Start Date*: 2005-12-09
    Sponsor Name:Greater Glasgow NHS Health Board / University of Glasgow co-sponsorship
    Full Title: New therapeutic targets in stroke prevention: the effect of allopurinol on the cerebral vasculature of patients with subcortical stroke
    Medical condition: Subcortical Ischaemic Stroke
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-004529-57 Sponsor Protocol Number: 06/AM/108 Start Date*: 2008-09-08
    Sponsor Name:Greenpark Healthcare Trust
    Full Title: Vascular Pleiotrophic Effects of Bisphosphonates in Post Menopausal Women with Osteoporosis: Cellular Mechanisms and Functional Consequences
    Medical condition: osteoporosis cardiovascular disease
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-012707-26 Sponsor Protocol Number: Acetilcisteina-Ocronosi-SI/2009 Start Date*: 2010-05-27
    Sponsor Name:AZIENDA OSPEDALIERA SENESE
    Full Title: THERAPEUTIC EFFECTIIVENESS OF N-ACETYL-CYSTEINE AND ASCORBIC ACID IN PATIENTS WITH ALKAPTONURIA-OCHRONOSIS
    Medical condition: patient affected by alkaptonuria-ocronosis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-003756-39 Sponsor Protocol Number: RDEA594-303 Start Date*: 2012-04-10
    Sponsor Name:Ardea Biosciences, Inc.
    Full Title: A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled Study to Assess the Efficacy and Safety of Lesinurad Monotherapy Compared to Placebo in Subjects with Gout and an Intolerance or...
    Medical condition: Gout
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10018627 Gout PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-001670-27 Sponsor Protocol Number: CSO1 Start Date*: 2005-11-14
    Sponsor Name:Greater Glasgow NHS Health Board / University of Glasgow co-sponsorship
    Full Title: Reversibility of cerebrovascular endothelial dysfunction in diabetes: the role of allopurinol.
    Medical condition: Type Two Diabetes Mellitus
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-001640-56 Sponsor Protocol Number: PI12/01866 Start Date*: 2014-01-31
    Sponsor Name:Fundación Para la Investigación Biomédica de Córdoba
    Full Title: Crossover clinical trial, randomized, double blind, placebo controlled trial. Modulation of cellular mediators and repair endothelial damage in patients with chronic renal disease through inhibitio...
    Medical condition: Patients with chronic kidney disease and asymptomatic hyperuricemia on the balance of mechanisms of vascular injury and repair.
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004849 10007648 Cardiovascular disease, unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 09:09:52 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA